Literature DB >> 33505963

Cynaropicrin Shows Antitumor Progression Potential in Colorectal Cancer Through Mediation of the LIFR/STATs Axis.

Dandan Zheng1,2,3, Yu Zhu1,2,3, Yili Shen1,2,3, Sisi Xiao1,2,3, Lehe Yang1, Youqun Xiang1, Xuanxuan Dai1, Wanle Hu4, Bin Zhou4, Zhiguo Liu1,2, Haiyang Zhao3, Chengguang Zhao1,2, Xiaoying Huang1, Liangxing Wang1.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is the second deadliest malignant disease in the world and the leukemia inhibitory factor receptor/signal transducers and activators of transcriptions (LIFR/STATs) signaling axis plays an important role in the molecular biology of CRC.
METHODS: Cell function tests were performed to observe the inhibitory effect of cynaropicrin on human CRC cells (RKO, HCT116, and DLD-1). Expression levels of LIFR, P-STAT3, P-STAT4, and apoptotic proteins were detected by Western blotting. Immunoprecipitation confirmed the presence of LIFR/STAT3/STAT4 complex. Cell immunofluorescence assay was used to observe the subcellular localization of STAT3 and STAT4. In vivo efficacy of cynaropicrin was evaluated by a xenotransplantation model in nude mice.
RESULTS: Cynaropicrin significantly reduced the survival ability of human CRC cells and promoted apoptosis in a dose-dependent manner. Western blotting results suggested that the antitumor effects of cynaropicrin might be mediated by inhibition of the LIFR/STATs axis. Cynaropicrin reduced the formation of STAT3/STAT4 heterodimers and blocked their entry into the nucleus. Cynaropicrin also suppressed tumor growth in the xenograft model.
CONCLUSION: The results showed that cynaropicrin exerted a strong inhibitory effect on CRC in vitro and in vivo. Our study concluded that cynaropicrin has potential application prospects in the field of anti-CRC therapy.
Copyright © 2021 Zheng, Zhu, Shen, Xiao, Yang, Xiang, Dai, Hu, Zhou, Liu, Zhao, Zhao, Huang and Wang.

Entities:  

Keywords:  CRC; LIFR; STATs; cynaropicrin; inhibitor

Year:  2021        PMID: 33505963      PMCID: PMC7829511          DOI: 10.3389/fcell.2020.605184

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  37 in total

Review 1.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

2.  Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway.

Authors:  Jialiang Shao; Wencheng Zhu; Yufeng Ding; Hongwen Zhu; Xiaoqian Jing; Hua Yu; Mujun Lu; Yunbo Qiao; Xiang Wang; Hua Ai; Xiongjun Wang
Journal:  Cancer Lett       Date:  2019-03-06       Impact factor: 8.679

3.  Mutation, methylation and expression analysis of LIFR gene in Indian breast cancer patients.

Authors:  Sumayya Abdul Sattar Real; Farah Parveen; Asad Ur Rehman; Rahimunnisa Shaik; S V S Deo; Syed Akhtar Husain
Journal:  Mutat Res       Date:  2019-08-12       Impact factor: 2.433

Review 4.  The potential and controversy of targeting STAT family members in cancer.

Authors:  Yannick Verhoeven; Sam Tilborghs; Julie Jacobs; Jorrit De Waele; Delphine Quatannens; Christophe Deben; Hans Prenen; Patrick Pauwels; Xuan Bich Trinh; An Wouters; Evelien L J Smits; Filip Lardon; Peter A van Dam
Journal:  Semin Cancer Biol       Date:  2019-10-09       Impact factor: 15.707

5.  STAT4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation.

Authors:  Yanan S Zhang; Dazhuan E Xin; Zhizhang Wang; Xinyang Song; Yanyun Sun; Quanli C Zou; Jichen Yue; Chenxi Zhang; Junxun M Zhang; Zhi Liu; Xiaoren Zhang; Ting C Zhao; Bing Su; Y Eugene Chin
Journal:  EMBO J       Date:  2019-02-15       Impact factor: 11.598

6.  STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers.

Authors:  Teppei Morikawa; Yoshifumi Baba; Mai Yamauchi; Aya Kuchiba; Katsuhiko Nosho; Kaori Shima; Noriko Tanaka; Curtis Huttenhower; David A Frank; Charles S Fuchs; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2011-02-10       Impact factor: 12.531

7.  Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators.

Authors:  Hung N Nguyen; Erika H Noss; Fumitaka Mizoguchi; Christine Huppertz; Kevin S Wei; Gerald F M Watts; Michael B Brenner
Journal:  Immunity       Date:  2017-02-21       Impact factor: 31.745

8.  Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells.

Authors:  Chengguang Zhao; Lehe Yang; Feng Zhou; Yun Yu; Xiaojing Du; Youqun Xiang; Chenglong Li; Xiaoying Huang; Congying Xie; Zhiguo Liu; Jiayuh Lin; Liangxing Wang; Guang Liang; Ri Cui
Journal:  Oncogene       Date:  2020-04-02       Impact factor: 9.867

9.  LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker.

Authors:  Dahu Chen; Yutong Sun; Yongkun Wei; Peijing Zhang; Abdol Hossein Rezaeian; Julie Teruya-Feldstein; Sumeet Gupta; Han Liang; Hui-Kuan Lin; Mien-Chie Hung; Li Ma
Journal:  Nat Med       Date:  2012-09-23       Impact factor: 53.440

10.  Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130.

Authors:  Martin J Boulanger; Alexander J Bankovich; Tanja Kortemme; David Baker; K Christopher Garcia
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  3 in total

1.  Network pharmacology and experimental verification based research into the effect and mechanism of Aucklandiae Radix-Amomi Fructus against gastric cancer.

Authors:  Siyuan Song; Jiayu Zhou; Ye Li; Jiatong Liu; Jingzhan Li; Peng Shu
Journal:  Sci Rep       Date:  2022-06-07       Impact factor: 4.996

2.  The Sesquiterpene Lactone Cynaropicrin Manifests Strong Cytotoxicity in Glioblastoma Cells U-87 MG by Induction of Oxidative Stress.

Authors:  Rossella Rotondo; Maria Antonietta Oliva; Antonietta Arcella
Journal:  Biomedicines       Date:  2022-07-02

3.  Suppression of endoplasmic reticulum stress-dependent autophagy enhances cynaropicrin-induced apoptosis via attenuation of the P62/Keap1/Nrf2 pathways in neuroblastoma.

Authors:  Randong Yang; Shurong Ma; Ran Zhuo; Lingqi Xu; Siqi Jia; Pengcheng Yang; Ye Yao; Haibo Cao; Liya Ma; Jian Pan; Jian Wang
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.